Emcure Pharma Soars 3% on Weight-Loss Injection Boost; Analyst Recommends 'Buy on Dips'

• Emcure Pharma shares jumped nearly 3% to a 52-week high of Rs 1,568.30, before closing marginally lower at Rs 1,522.
• The stock's surge is driven by the recent commercial launch of Poviztra, a semaglutide weight-loss injection in India.
• Emcure secured exclusive rights to distribute and commercialize Poviztra in India through a partnership with Novo Nordisk India.
• Analyst Drumil Vithlani of Bonanza noted a "strong bullish breakout" with increased volumes, indicating fresh buying interest.
• Vithlani advises a 'buy on dips' strategy around Rs 1,480-1,500, targeting an upside potential of Rs 1,580-1,620.

Why It Matters: Emcure Pharma's stock surged on its weight-loss injection launch, with analysts recommending buying on dips.